Therapie schwerer akneiformer Cetuximab-Exantheme mit oralem Retinoid, topischem Antibiotikum und Steroidexternum
作者： A. Wollenberg , N. Moosmann , J. Kroth , V. Heinemann , E. Klein
DOI: 10.1007/S00105-006-1256-Y
关键词:
摘要: The biological agent cetuximab specifically inhibits the epidermal growth factor receptor (EGFR) function. Cetuximab is licensed for treatment of metastatic colorectal carcinoma, as it enhances efficacy cytostatic therapy. Acneiform drug eruptions are common side effects. We report two patients with who developed a severe acneiform eruption on face and upper part body during cetuximab. Triple therapy consisting systemic isotretinoin, topical nadifloxacin corticosteroid produced rapid improvement moderate cheilitis only effect. conclude that triple an effective caused by
springer.com
sci-hub.se 参考文章(12)
R. Gutzmer, T. Werfel, A. Kapp, J. Elsner, Kutane Nebenwirkungen einer EGF-Rezeptor-Blockade und deren Management Hautarzt. ,vol. 57, pp. 509- 513 ,(2006) , 10.1007/S00105-005-1033-3
Hideo Masui, Ian Altas, John Mendelsohn, Zhen Fan, Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies Cancer Research. ,vol. 53, pp. 4322- 4328 ,(1993)
Siegfried Segaert, Josep Tabernero, Olivier Chosidow, Thomas Dirschka, Joern Elsner, Luca Mancini, Tim Maughan, Jean-Franuois Morere, Armando Santoro, Alberto Sobrero, Eric Van Cutsem, Alison Layton, The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. Journal Der Deutschen Dermatologischen Gesellschaft. ,vol. 3, pp. 599- 606 ,(2005) , 10.1111/J.1610-0387.2005.05058.X
Koji Murata, Kazunari Sugita, Miwa Kobayashi, Kenji Kabashima, Yoshiki Tokura, Nadifloxacin downmodulates antigen-presenting functions of epidermal Langerhans cells and keratinocytes Journal of Dermatological Science. ,vol. 42, pp. 91- 99 ,(2006) , 10.1016/J.JDERMSCI.2005.12.008
R.I Nicholson, J.M.W Gee, M.E Harper, EGFR and cancer prognosis. European Journal of Cancer. ,vol. 37, pp. 9- 15 ,(2001) , 10.1016/S0959-8049(01)00231-3
K.J. Busam, P. Capodieci, R. Motzer, T. Kiehn, D. Phelan, A.C. Halpern, Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. British Journal of Dermatology. ,vol. 144, pp. 1169- 1176 ,(2001) , 10.1046/J.1365-2133.2001.04226.X
R. Gutzmer, T. Werfel, R. Mao, A. Kapp, J. Elsner, Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. British Journal of Dermatology. ,vol. 153, pp. 849- 851 ,(2005) , 10.1111/J.1365-2133.2005.06835.X
Neelam T. Shah, Mark G. Kris, William Pao, Leslie B. Tyson, Barbara M. Pizzo, Murk-Hein Heinemann, Leah Ben-Porat, Dana L. Sachs, Robert T. Heelan, Vincent A. Miller, Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib Journal of Clinical Oncology. ,vol. 23, pp. 165- 174 ,(2005) , 10.1200/JCO.2005.04.057
Marion Harris, Monoclonal antibodies as therapeutic agents for cancer Lancet Oncology. ,vol. 5, pp. 292- 302 ,(2004) , 10.1016/S1470-2045(04)01467-6
David Cunningham, Yves Humblet, Salvatore Siena, David Khayat, Harry Bleiberg, Armando Santoro, Danny Bets, Matthias Mueser, Andreas Harstrick, Chris Verslype, Ian Chau, Eric Van Cutsem, None, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 351, pp. 337- 345 ,(2004) , 10.1056/NEJMOA033025